MapLight Therapeutics (MPLT) grants RSUs and options to Chief Discovery Officer

Rhea-AI Filing Summary

MapLight Therapeutics Chief Discovery Officer Anatol Kreitzer reported equity awards of 6,020 restricted stock units and 24,455 employee stock options dated February 5, 2026. The RSUs vest 25% on January 1, 2027, with the remaining 75% vesting in equal quarterly installments, subject to continued service.

The options have a $15.70 exercise price and begin vesting with 25% on February 5, 2027, then monthly vesting for the remaining shares. Following the RSU grant, Kreitzer directly holds 259,928 shares of voting common stock, and 24,455 options after the option grant.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Kreitzer Anatol

Role Chief Discovery Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	24,455	$0.00	--
Grant/Award	Voting Common Stock	6,020	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 24,455 shares (Direct); Voting Common Stock — 259,928 shares (Direct)

Footnotes (1)

1. Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on January 1, 2027, and 1/16th of the RSUs shall vest on each subsequent April 1, July 1, October 1 and January 1 thereafter, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. 1/4th of the total shares underlying the option shall vest on February 5, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kreitzer Anatol

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Discovery Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	02/05/2026		A		6,020(1)	A	$0(2)	259,928	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$15.7	02/05/2026		A		24,455		(3)	02/04/2036	Voting Common Stock	24,455	$0	24,455	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on January 1, 2027, and 1/16th of the RSUs shall vest on each subsequent April 1, July 1, October 1 and January 1 thereafter, subject to the Reporting Person's continued service through each vesting date.

2. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.

3. 1/4th of the total shares underlying the option shall vest on February 5, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did MPLT Chief Discovery Officer Anatol Kreitzer report?

Anatol Kreitzer reported receiving 6,020 restricted stock units and 24,455 employee stock options dated February 5, 2026. These are equity compensation grants, not open-market purchases, and both awards are subject to multi-year vesting tied to his continued service with MapLight Therapeutics.

How do the new MPLT restricted stock units granted to Anatol Kreitzer vest?

The 6,020 RSUs vest 25% on January 1, 2027, with the remaining 75% vesting in equal installments on each April 1, July 1, October 1, and January 1 thereafter. Vesting requires Kreitzer to remain in service with MapLight through each vesting date.

What are the key terms of Anatol Kreitzer’s new MPLT stock options?

Kreitzer received 24,455 employee stock options with a $15.70 exercise price, granted February 5, 2026. One quarter of the options vest on February 5, 2027, and the remaining three quarters vest in equal monthly installments, contingent on continued service, until the February 4, 2036 expiration.

How many MPLT shares does Anatol Kreitzer own after these Form 4 transactions?

After the RSU grant, Kreitzer beneficially owns 259,928 shares of voting common stock directly. In addition, he holds 24,455 employee stock options. The RSUs each represent a contingent right to receive one share of voting common stock as they vest over time.

Are Anatol Kreitzer’s new MPLT equity awards open-market purchases?

No. The Form 4 lists both the 6,020 RSUs and 24,455 employee stock options with a transaction code “A,” indicating awards granted by the company. The reported per-share price is $0 for the grants, reflecting compensation rather than market transactions.

What role does Anatol Kreitzer hold at MapLight Therapeutics (MPLT)?

Anatol Kreitzer is identified as an officer of MapLight Therapeutics, serving as Chief Discovery Officer. The Form 4 indicates he is not a director and not a 10% owner, and it reports his directly held common stock and stock option awards as of the grant date.